Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis

Fig. 3

TSC1-2 complex activation and effect on mTOR pathway. TSC1-2 forms a complex with the GTPase domain of Rheb, converting it to its inactive, Rheb-GDP form. A loss of function mutation in TSC1-2 leads to increased levels and unopposed action of Rheb-GTP on mTORC1, leading to constant cell growth. Additionally, loss of function of TSC1-2 hinders mTORC2 activation

Back to article page